What is the current Price Target for the Kintara Therapeutics Inc stock?

The average Kintara Therapeutics Inc target price is $10.13. This is 301.79% higher than the current stock price. The highest price target is 336.51%, the lowest is 267.06%. 2 Analysts have issued a price target Kintara Therapeutics Inc 2026 .

How high will the Kintara Therapeutics Inc stock rise?

No reliable answer can be given as to how high the Kintara Therapeutics Inc stock will rise. The performance of stocks, including the Kintara Therapeutics Inc stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Kintara Therapeutics Inc stock today?

The performance of Kintara Therapeutics Inc stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Kintara Therapeutics Inc stock fall?

The decline in Kintara Therapeutics Inc stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Kintara Therapeutics Inc Forecast, price target & analysts

$2.39

5.16% today

Nasdaq, Feb 28, 08:19 pm CET

ISIN

US49720K1016

Symbol

HURA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Trade

Industry

Wholesale

Overview Dividends Analysts Charts News Strategies

Kintara Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Kintara Therapeutics Inc Classifications & Recommendation:

Buy

100%

Kintara Therapeutics Inc Price Target

Target Price	$10.13
Price	$2.52
Potential	301.79% register free of charge
Number of Estimates	2

	2 Analysts have issued a price target Kintara Therapeutics Inc 2026 . The average Kintara Therapeutics Inc target price is $10.13. This is 301.79% register free of charge higher than the current stock price. The highest price target is $11.00 336.51% register free of charge , the lowest is $9.25 267.06% register free of charge .
	A rating was issued by 1 analysts: 1 Analysts recommend Kintara Therapeutics Inc to buy, 0 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Kintara Therapeutics Inc stock has an average upside potential 2026 of 301.79% register free of charge . Most analysts recommend the Kintara Therapeutics Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2030

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Jun '24	2025 Estimates
Earnings Per Share $	-11.29	-0.42
	96.52%	96.28%
P/E		negative

1 Analysts have issued a Kintara Therapeutics Inc forecast for earnings per share. The average Kintara Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-11.29	96.52%
2025	$-0.42 96.28% Unlock

Current	-0.03	50.00%
2025	-12.55 41,733.33% Unlock

Kintara Therapeutics Inc...

Current Kintara Therapeutics Inc Upgrades & Downgrades Beta

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Rodman & Renshaw	Locked ➜ Locked	Locked	Dec 19 2024

Analyst Rating	Date
Locked Rodman & Renshaw: Locked ➜ Locked	Dec 19 2024

Discover more stocks with a high price target

Coinbase Global, Inc. 60.51%

BioNTech SE - ADR 30.07%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now